Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma (ESCC) Patients as Postoperative Adjuvant Therapy. In order to observe and evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules combined with TQB2450 Injection in treatment of patients with ESCC. The primary endpoint is disease free survival (DFS).
Esophageal Squamous Cell Carcinoma|Esophageal Neoplasms|Esophageal Diseases|Gastrointestinal Neoplasms|Gastrointestinal Diseases|Digestive System Neoplasms|Digestive System Diseases|Neoplasms by Site|Neoplasms by Histologic Type|Neoplasms, Squamous Cell|Carcinoma, Squamous Cell
DRUG: Anlotinib hydrochloride|DRUG: TQB2450
DFS, Disease Free Survival, DFS was defined as the time from the day patients received first dose of treatment regimen until the date of first documented recurrence or death from any cause, whichever come first, assessed up to 96 months.
1-year DFS rate, One year Disease Free Survival rate, 1-year DFS rate was disease-free survival rate at the time since patients received first dose of treatment regimen for one year.|3-year DFS rate, Three year Disease Free Survival rate, 3-year DFS rate was disease-free survival rate at the time since patients received first dose of treatment regimen for 3 years.|1-year OS rate, One year Overall Survival rate, 1-year OS rate was overall survival rate at the time since patients received first dose of treatment regimen for one year.|3-year OS rate, Three year Overall Survival rate, 3-year OS rate was overall survival rate at the time since patients received first dose of treatment regimen for 3 years.
This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma (ESCC) Patients as Postoperative Adjuvant Therapy. In order to observe and evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules combined with TQB2450 Injection in treatment of patients with Esophageal Squamous Cell Carcinoma (ESCC). Primary Efficacy Endpoint: Disease Free Survival (DFS) (According to RECIST Version 1.1), Secondary Efficacy Endpoints:1-year DFS rate, 3-year DFS rate, 1-year Overall Survival (OS) rate, 3-year OS rate, and Safety. Safety and tolerance will be evaluated by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 5.0.